Systemic immune-inflammation index is a stage-dependent prognostic factor in patients with operable non-small cell lung cancer.

ABSTRACT:

Background

Immune function is a key component affecting tumor progression in patients with cancer. The purpose of this study was to identify the prognostic value of systemic immune-inflammation index (SII) in patients with non-small cell lung cancer (NSCLC) and the differences of its prognostic value in patients with distinct characteristics.

Methods

Patients with completely resected NSCLC were reviewed according to the eighth TNM classification of lung cancer. Patients were further categorized into the low- and high-SII groups. Cox proportional hazard analyses were performed to identify the independent prognostic factors.

Results

A total of 3984 patients with NSCLC were enrolled in this study. Kaplan-Meier analyses demonstrated that high SII was associated with worse

SUBMITTER: Fu F 

PROVIDER: S-EPMC8350100 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature